150 related articles for article (PubMed ID: 22308284)
1. Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies.
Kroeze LI; Nikoloski G; da Silva-Coelho P; van Hoogen P; Stevens-Linders E; Kuiper RP; Schnittger S; Haferlach T; Pahl HL; van der Reijden BA; Jansen JH
Blood; 2012 Feb; 119(5):1318-9. PubMed ID: 22308284
[No Abstract] [Full Text] [Related]
2. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
Puda A; Milosevic JD; Berg T; Klampfl T; Harutyunyan AS; Gisslinger B; Rumi E; Pietra D; Malcovati L; Elena C; Doubek M; Steurer M; Tosic N; Pavlovic S; Guglielmelli P; Pieri L; Vannucchi AM; Gisslinger H; Cazzola M; Kralovics R
Am J Hematol; 2012 Mar; 87(3):245-50. PubMed ID: 22190018
[TBL] [Abstract][Full Text] [Related]
3. Recurrent genetic defects on chromosome 7q in myeloid neoplasms.
Hosono N; Makishima H; Jerez A; Yoshida K; Przychodzen B; McMahon S; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Gómez-Seguí I; Verma AK; McDevitt MA; Sekeres MA; Ogawa S; Maciejewski JP
Leukemia; 2014 Jun; 28(6):1348-51. PubMed ID: 24429498
[No Abstract] [Full Text] [Related]
4. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.
Makishima H; Jankowska AM; Tiu RV; Szpurka H; Sugimoto Y; Hu Z; Saunthararajah Y; Guinta K; Keddache MA; Putnam P; Sekeres MA; Moliterno AR; List AF; McDevitt MA; Maciejewski JP
Leukemia; 2010 Oct; 24(10):1799-804. PubMed ID: 20724984
[No Abstract] [Full Text] [Related]
5. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylated in cancer 1 (HIC1) recruits polycomb repressive complex 2 (PRC2) to a subset of its target genes through interaction with human polycomb-like (hPCL) proteins.
Boulay G; Dubuissez M; Van Rechem C; Forget A; Helin K; Ayrault O; Leprince D
J Biol Chem; 2012 Mar; 287(13):10509-10524. PubMed ID: 22315224
[TBL] [Abstract][Full Text] [Related]
8. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.
Abdel-Wahab O; Pardanani A; Patel J; Wadleigh M; Lasho T; Heguy A; Beran M; Gilliland DG; Levine RL; Tefferi A
Leukemia; 2011 Jul; 25(7):1200-2. PubMed ID: 21455215
[No Abstract] [Full Text] [Related]
9. Regulation of CD11b transcription by decreasing PRC2 and increased acH4 level during ATRA-induced HL-60 differentiation.
Tang H; Chen F; Tan Q; Tan S; Liu L; Zhang F
Acta Biochim Biophys Sin (Shanghai); 2009 Jul; 41(7):588-93. PubMed ID: 19578722
[TBL] [Abstract][Full Text] [Related]
10. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.
Ntziachristos P; Tsirigos A; Van Vlierberghe P; Nedjic J; Trimarchi T; Flaherty MS; Ferres-Marco D; da Ros V; Tang Z; Siegle J; Asp P; Hadler M; Rigo I; De Keersmaecker K; Patel J; Huynh T; Utro F; Poglio S; Samon JB; Paietta E; Racevskis J; Rowe JM; Rabadan R; Levine RL; Brown S; Pflumio F; Dominguez M; Ferrando A; Aifantis I
Nat Med; 2012 Feb; 18(2):298-301. PubMed ID: 22237151
[TBL] [Abstract][Full Text] [Related]
11. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
12. A model for transmission of the H3K27me3 epigenetic mark.
Hansen KH; Bracken AP; Pasini D; Dietrich N; Gehani SS; Monrad A; Rappsilber J; Lerdrup M; Helin K
Nat Cell Biol; 2008 Nov; 10(11):1291-300. PubMed ID: 18931660
[TBL] [Abstract][Full Text] [Related]
13. EZH2 in Myeloid Malignancies.
Rinke J; Chase A; Cross NCP; Hochhaus A; Ernst T
Cells; 2020 Jul; 9(7):. PubMed ID: 32650416
[TBL] [Abstract][Full Text] [Related]
14. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A
J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139
[TBL] [Abstract][Full Text] [Related]
15. Clinical Evaluation of a Novel Nine-Gene Panel for Ion Torrent PGM Sequencing of Myeloid Malignancies.
Ivanova M; Shivarov V; Pavlov I; Lilakos K; Naumova E
Mol Diagn Ther; 2016 Feb; 20(1):27-32. PubMed ID: 26476543
[TBL] [Abstract][Full Text] [Related]
16. The transcriptional repression by NIPP1 is mediated by Polycomb group proteins.
Roy N; Van Eynde A; Beke L; Nuytten M; Bollen M
Biochim Biophys Acta; 2007; 1769(9-10):541-5. PubMed ID: 17804093
[TBL] [Abstract][Full Text] [Related]
17. HDAC inhibitors conquer Polycomb proteins.
Yaswen P
Cell Cycle; 2010 Jul; 9(14):2705. PubMed ID: 20676029
[No Abstract] [Full Text] [Related]
18. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
19. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene.
Kotake Y; Cao R; Viatour P; Sage J; Zhang Y; Xiong Y
Genes Dev; 2007 Jan; 21(1):49-54. PubMed ID: 17210787
[TBL] [Abstract][Full Text] [Related]
20. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J
Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
